Related Experiment Video

Updated: Jan 9, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.4K

Correction: TACE-HAlC combined with Donafenib and immune checkpoint inhibitors for BCLC stage C HCC patients (THEME

Linan Yin1, Weihang Li1, Wencheng Shao2

  • 1Department of Interventional Radiology, Harbin Medical University Cancer Hospital, Harbin, China.

Frontiers in Immunology
|December 8, 2025
PubMed

Insights

This study corrects a previous article DOI. It ensures accurate citation and retrieval of research findings for improved scientific communication and data integrity.

Area of Science:

  • Immunology
  • Scientific Publishing

Background:

  • Accurate citation is crucial for scientific integrity.
  • Proper referencing ensures reproducibility and facilitates knowledge dissemination.

Purpose of the Study:

  • To correct the Digital Object Identifier (DOI) for a previously published article.
  • To ensure the scientific record is accurate and retrievable.

Main Methods:

  • A correction notice was issued.
  • The correct DOI was identified and published.

Main Results:

  • The incorrect DOI has been rectified.
  • The article is now accurately linked and accessible.

Conclusions:

  • This correction enhances the reliability of the scientific literature.
  • Ensuring DOI accuracy supports the scientific community's access to research.

Keywords:
Donafenibhepatic arterial infusion chemotherapyhepatocellular carcinomaimmune checkpoint inhibitorstransarterial chemoembolization

More Related Videos

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization09:49

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

10.7K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.0K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K